← Leaderboards
Joseph Mark Metzger
University Of Minnesota
$31,677,280
Attributed
$31,677,280
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,502,831 · 15
By mechanism
R01$29,252,183 · 10
P01$10,026,300 · 3
T32$617,234 · 1
P30$607,114 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota
Same institution · by research overlap
- John Meitzen$3,198,912
- Steve Davidson$4,103,581
- Michelle A Calabrese$456,156
Others in their field
Top investigators on “Myocardium”
- Lynn A Sleeper · New England Research Institutes, Inc.$41,686,119
- Piero Anversa · New York Medical College$37,744,132
- Walter J Koch · Duke University$32,189,425
- Deepak Srivastava · J. David Gladstone Institutes$25,431,561
- Jianyi Zhang · University Of Alabama At Birmingham$23,901,556
- Ju Chen · University Of California, San Diego$23,492,230
Research focus
MyocardiumCardiacPerformanceGeneticPhysiologicalIn VivoStriated MusclesCardiac MyocytesBaseMuscle CellsFunctional DisorderHeartSarcomeresPublic Health RelevanceTroponinInheritedComplexCardiomyopathiesGenesHeart FailureHeart FunctionInsightMuscleRodent
Grant awards (96)
Myofilaments as regulators of heart function in disease$553,562
R01 · FY2025 · HL · contact PI
Skeletal muscle sarcomere function in health and disease$514,743
R01 · FY2025 · AR · contact PI
Inclusive Excellence Training Program in the Systems Biology of Cardiovascular Inflammation$197,212
T32 · FY2025 · HL · contact PI
Myofilaments as regulators of heart function in disease$542,491
R01 · FY2024 · HL · contact PI
Skeletal muscle sarcomere function in health and disease$514,743
R01 · FY2024 · AR · contact PI
Inclusive Excellence Training Program in the Systems Biology of Cardiovascular Inflammation$213,776
T32 · FY2024 · HL · contact PI
Myofilaments as regulators of heart function in disease$553,562
R01 · FY2023 · HL · contact PI
Skeletal muscle sarcomere function in health and disease$531,074
R01 · FY2023 · AR · contact PI
Inclusive Excellence Training Program in the Systems Biology of Cardiovascular Inflammation$206,246
T32 · FY2023 · HL · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$632,339
R01 · FY2022 · HL · contact PI
Myofilaments as regulators of heart function in disease$551,404
R01 · FY2022 · HL · contact PI
Skeletal muscle sarcomere function in health and disease$544,002
R01 · FY2022 · AR · contact PI
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo$461,671
R01 · FY2022 · AR · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$632,339
R01 · FY2021 · HL · contact PI
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo$452,345
R01 · FY2021 · AR · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$632,339
R01 · FY2020 · HL · contact PI
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo$466,335
R01 · FY2020 · AR · contact PI
Dystrophin and Heart Disease$383,310
R01 · FY2020 · HL · contact PI
Myofilaments as regulators of heart function in disease$383,126
R01 · FY2020 · HL · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$632,339
R01 · FY2019 · HL · contact PI
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo$466,335
R01 · FY2019 · AR · contact PI
Dystrophin and Heart Disease$383,310
R01 · FY2019 · HL · contact PI
Myofilaments as regulators of heart function in disease$383,126
R01 · FY2019 · HL · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$654,538
R01 · FY2018 · HL · contact PI
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo$465,840
R01 · FY2018 · AR · contact PI
Dystrophin and Heart Disease$383,310
R01 · FY2018 · HL · contact PI
Myofilaments as regulators of heart function in disease$382,511
R01 · FY2018 · HL · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$654,538
R01 · FY2017 · HL · contact PI
Dystrophin and Heart Disease$380,841
R01 · FY2017 · HL · contact PI
Myofilaments as regulators of heart function in disease$380,046
R01 · FY2017 · HL · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$654,538
R01 · FY2016 · HL · contact PI
Targeted membrane integrity in cardiac ischemia and reperfusion$654,538
R01 · FY2015 · HL · contact PI
Troponin and Heart Function in Health and Disease$376,123
R01 · FY2014 · HL · contact PI
Dystrophin Function in Aging Heart$344,664
R01 · FY2014 · AG · contact PI
Troponin and Heart Function in Health and Disease$365,376
R01 · FY2013 · HL · contact PI
Dystrophin Function in Aging Heart$325,707
R01 · FY2013 · AG · contact PI
Troponin and Heart Function in Health and Disease$383,798
R01 · FY2012 · HL · contact PI
Dystrophin Function in Aging Heart$344,665
R01 · FY2012 · AG · contact PI
Troponin and Heart Function in Health and Disease$383,798
R01 · FY2011 · HL · contact PI
Dystrophin Function in Aging Heart$344,664
R01 · FY2011 · AG · contact PI
Chemical-based membrane sealants for dystrophic muscle$501,827
R01 · FY2010 · HL · contact PI
Troponin and Heart Function in Health and Disease$387,674
R01 · FY2010 · HL · contact PI
Genetic modification of heart performance$356,648
R01 · FY2010 · HL · contact PI
Dystrophin Function in Aging Heart$348,144
R01 · FY2010 · AG · contact PI
Chemical-based membrane sealants for dystrophic muscle$499,232
R01 · FY2009 · HL · contact PI
Troponin and Heart Function in Heath and Disease$358,882
R01 · FY2009 · HL · contact PI
Genetic modification of heart performance$356,648
R01 · FY2009 · HL · contact PI
CORE--IN VIVO FUNCTIONALITY$157,437
P30 · FY2009 · AG · contact PI
Troponin and Heart Function in Heath and Disease$358,882
R01 · FY2008 · HL · contact PI
Chemical-based membrane sealants for dystrophic muscle$352,998
R01 · FY2008 · HL · contact PI
Genetic modification of heart performance$247,618
R01 · FY2008 · HL · contact PI
CORE--IN VIVO FUNCTIONALITY$164,623
P30 · FY2008 · AG · contact PI
Genetic modification of heart performance$111,264
R01 · FY2008 · HL · contact PI
Chemical-based membrane sealants for dystrophic muscle$100,022
R01 · FY2008 · HL · contact PI
Genetic Modification of Muscle In Aging and Disease$1,129,479
P01 · FY2007 · AG · contact PI
Chemical-based membrane sealants for dystrophic muscle$462,699
R01 · FY2007 · HL · contact PI
Genetic modification of heart performance$358,882
R01 · FY2007 · HL · contact PI
Troponin and Heart Function in Heath and Disease$358,882
R01 · FY2007 · HL · contact PI
Mutant Sarcomeric Proteins and Cardiac Disease$282,430
R01 · FY2007 · HL · contact PI
GENETIC MODIFICATION OF THE HEART IN AGING AND DISEASE$246,958
P01 · FY2007 · AG · contact PI
CORE--IN VIVO FUNCTIONALITY$136,896
P30 · FY2007 · AG · contact PI
Genetic Modification of Muscle In Aging and Disease$67,000
P01 · FY2007 · AG · contact PI
Administrative Leadership Core$58,199
P01 · FY2007 · AG · contact PI
Mutant Sarcomeric Proteins and Cardiac Disease$38,052
R01 · FY2007 · HL · contact PI
Genetic Modification of Muscle In Aging and Disease$1,207,939
P01 · FY2006 · AG · contact PI
Troponin and Heart Function in Heath and Disease$369,600
R01 · FY2006 · HL · contact PI
Genetic modification of heart performance$369,600
R01 · FY2006 · HL · contact PI
Mutant Sarcomeric Proteins and Cardiac Disease$332,538
R01 · FY2006 · HL · contact PI
GENETIC MODIFICATION OF THE HEART IN AGING AND DISEASE$228,731
P01 · FY2006 · AG · contact PI
CORE--IN VIVO FUNCTIONALITY$75,158
P30 · FY2006 · AG · contact PI
Genetic Modification of Muscle In Aging and Disease$1,212,874
P01 · FY2005 · AG
Mutant Sarcomeric Proteins and Cardiac Disease$362,996
R01 · FY2005 · HL
Genetic engineering of heart performance$358,288
R01 · FY2005 · HL
Troponin and Heart Function in Health and Disease$295,025
R01 · FY2005 · HL
CORE--IN VIVO FUNCTIONALITY$73,000
P30 · FY2005 · AG
Genetic Modification of Muscle In Aging and Disease$1,185,714
P01 · FY2004 · AG
Mutant Sarcomeric Proteins and Cardiac Disease$365,540
R01 · FY2004 · HL
Genetic engineering of heart performance$358,288
R01 · FY2004 · HL
Troponin and Heart Function in Health and Disease$295,344
R01 · FY2004 · HL
Genetic Modification of Muscle In Aging and Disease$1,162,013
P01 · FY2003 · AG
Genetic engineering of heart performance$358,288
R01 · FY2003 · HL
Troponin and Heart Function in Health and Disease$295,655
R01 · FY2003 · HL
MUTANT SARCOMERIC PROTEINS AND CARDIAC DISEASE$284,501
R01 · FY2003 · HL
GENETIC MODIFICATION OF STRIATED MUSCLES DURING AGING$960,395
P01 · FY2002 · AG
Genetic engineering of heart performance$358,288
R01 · FY2002 · HL
Troponin and Heart Function in Health and Disease$345,352
R01 · FY2002 · HL
MUTANT SARCOMERIC PROTEINS AND CARDIAC DISEASE$276,215
R01 · FY2002 · HL
GENETIC MODIFICATION OF HEART FUNCTION IN VIVO$254,615
P01 · FY2002 · AG
GENETIC MODIFICATION OF STRIATED MUSCLES DURING AGING$956,605
P01 · FY2001 · AG
FUNCTION OF MYOFILAMENT PHOSPHOPROTEIN IN HEART$269,511
R01 · FY2001 · HL
MUTANT SARCOMERIC PROTEINS AND CARDIAC DISEASE$260,359
R01 · FY2001 · HL
GENETIC MODIFICATION OF HEART FUNCTION IN VIVO$254,615
P01 · FY2001 · AG
GENETIC MODIFICATION OF STRIATED MUSCLES DURING AGING$943,532
P01 · FY2000 · AG
FUNCTION OF MYOFILAMENT PHOSPHOPROTEIN IN HEART$261,662
R01 · FY2000 · HL
MUTANT SARCOMERIC PROTEINS AND CARDIAC DISEASE$260,359
R01 · FY2000 · HL
GENETIC MODIFICATION OF HEART FUNCTION IN VIVO$157,631
P01 · FY2000 · AG